[Special Stock] Gyeongnam Pharmaceutical, Domestic Hoarding Highlighted Amid Shortage of Chinese Cold Medicine Increase
[Asia Economy Reporter Jang Hyowon] Kyungnam Pharmaceutical is showing strong performance. It is interpreted to be influenced by news of shortages of cold medicine and antipyretics due to a surge in COVID-19 patients in China.
As of 10:39 AM on the 2nd, Kyungnam Pharmaceutical is trading at 3,090 KRW, up 15.11% compared to the previous day.
Recently, as China has eased its COVID-19 restrictions and a 'twindemic' of influenza and COVID-19 is occurring domestically, concerns about shortages of cold medicine are growing. In particular, cases of stockpiling cold medicine for smuggling into China have been reported.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- [Breaking] Samsung Labor-Management 'Performance Bonus Negotiations' Fail in Third Mediation... Union Says "General Strike to Proceed as Planned Tomorrow"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Kyungnam Pharmaceutical is primarily engaged in the manufacturing and wholesale and retail of pharmaceuticals and raw materials for pharmaceuticals, as well as the manufacturing and sales of health functional foods. It manufactures and sells various cold medicines, analgesics, antipyretics, and anti-inflammatory drugs, including Lemona, its founding product athlete's foot medicine PM, and sore throat treatment Minoleptroki.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
